
    
      -  To compare the single (Part A) and multiple dose (Part B) pharmacokinetic profiles and
           bioavailability of DDS-06C tablets with the immediate-release tablet reference products
           Zaldiar® and Ultracet®.

        -  To assess the effect of food on the pharmacokinetic profile of DDS-06C tablets following
           administration of a single oral dose.

        -  To monitor and record all adverse events.
    
  